Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Journal Title: OncoReview - Year 2011, Vol 1, Issue 1
Abstract
A phase 3 trial demonstrated superiority at interim analysis for everolimus over placebo in patients with metastatic renal cell carcinoma (mRCC) progressing on vascular endothelial growth factor receptor tyrosine kinase inhibitors. Final results and analysis of prognostic factors are reported.METHODS: Patients with mRCC (N=416) were randomized (2:1) to everolimus 10 mg/d (n=277) or placebo (n=139) plus best supportive care. Progression-free survival (PFS) and safety were assessed to the end of double-blind treatment. Mature overall survival (OS) data were analyzed, and prognostic factors for survival were investigated by multivariate analyses. A rank-preserving structural failure time model estimated the effect on OS, correcting for crossover from placebo to everolimus.RESULTS: The median PFS was 4.9 months (everolimus) versus 1.9 months (placebo) (hazard ratio [HR], 0.33; P <0.001) by independent central review and 5.5 months (everolimus) versus 1.9 months (placebo) (HR, 0.32; P <0.001) by investigators. Serious adverse events with everolimus, independent of causality, in ≥5% of patients included infections (all types, 10%), dyspnea (7%), and fatigue (5%). The median OS was 14.8 months (everolimus) versus 14.4 months (placebo) (HR 0.87; P=0.162), with 80% of patients in the placebo arm crossed over to everolimus. By the rank-preserving structural failure time model, the survival corrected for crossover was 1.9-fold longer (95% confidence interval, 0.5–8.5) with everolimus compared with placebo only. Independent prognostic factors for shorter OS in the study included low performance status, high corrected calcium, low hemoglobin, and prior sunitinib (P <0.01).CONCLUSIONS: These results established the efficacy and safety of everolimus in patients with mRCC after progression on sunitinib and/or sorafenib.
Authors and Affiliations
Robert J. Motzer
Keywords
Related Articles
- EP ID EP53095
- DOI -
- Views 271
- Downloads 0
Zasady postępowania diagnostyczno-terapeutycznego u chorych na nowotwory podścieliskowe przewodu pokarmowego (GIST) w 2010 roku
Nowotwory podścieliskowe przewodu pokarmowego (ang. gastrointestinal stromal tumors, GIST) są najczęstszymi nowotworami pochodzenia mezenchymalnego w obrębie przewodu pokarmowego. Nowotwory te, dzięki postępom w diagnost...
Receptory PPAR i ich znaczenie w nowotworach
Receptory aktywowane przez proliferatory peroksysomów (ang. peroxisome proliferator activated receptor, PPAR) należą do grupy szeroko rozpowszechnionych sterydowych receptorów jądrowych. Celem pracy było przedstawienie a...
Treatment of patients with multiple myeloma than 65–70 years of age and the role of maintenance therapy after transplantation stem cells
Treatment of myeloma has changed significantly in the past decade as results of better understanding of disease biology, more effective treatments, and improved supportive care. Autologous stem cell transplantation (SCT)...
Pleural effusion in patient with chronic myeloid leukemia treated with dasatinib - a case report
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with inherence of a cytogenetic abnormalities in the shape of translocation of gene ABL from chromosome 9 to chromosome 22, t(9,22)(q34;q11). Current standa...
Imatynib w terapii adiuwantowej pacjentów po zabiegu usunięcia nowotworów podścieliskowych przewodu pokarmowego (GIST) - przegląd systematyczny badań klicznych i metaanaliza
[b]Wstęp:[/b] Zastosowanie terapii adiuwantowej jest zalecane u pacjentów ze znaczącym ryzykiem nawrotu choroby po zabiegu usunięcia nowotworu podścieliskowego przewodu pokarmowego.[b]Cel pracy[/b]: Ocena skuteczności kl...